Van Hees S, et al. - Given that in patients with long-term viral suppression and negative HBeAg at the start of treatment, Nucleos(t)ide Analogue withdrawal results in significant hepatitis B surface antigen (HBsAg) loss which is often preceded by viral rebound with concomitant Alanine Aminotransferase flares, researchers analyzed a multicentric, international observational cohort of patients with Nucleos(t)ide Analogue induced HBeAg seroconversion to assess off-treatment HBsAg loss. Among 98 mono-infected, predominantly male (74.4%) chronic hepatitis B patients of mixed ethnicity (43.9% Asians, 49.0% Caucasians) who stopped treatment at a median of 11.4 (6.1-18.0) months after HBeAg seroconversion, 16 patients experienced hepatitis B surface antigen loss during a median follow-up of 42.8 months after treatment cessation: 14 off-treatment and 2 after retreatment initiation with subsequent long-term viral suppression. Observations revealed high HBsAg loss rates in correlation with persistent viral control after treatment cessation following NA induced HBeAg seroconversion in Caucasian patients.